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Elevated tumour interleukin-1b is associated with systemic
inflammation: a marker of reduced survival in gastro-oesophageal
cancer
DAC Deans1, SJ Wigmore1, H Gilmour1, S Paterson-Brown1, JA Ross1 and KCH Fearon*,1
1Tissue Injury and Repair Group, Department of Clinical and Surgical Sciences, MRC Centre for Inflammation Research, The Chancellor’s Building,
Edinburgh University, 49 Little France Crescent, Edinburgh EH16 4SB, UK
Systemic inflammation is associated with adverse prognosis cancer but its aetiology remains unclear. We investigated the expression
of proinflammatory cytokines within normal mucosa from healthy controls and tumour tissue in cancer patients and related these
levels with markers of systemic inflammation and with the presence of a tumour inflammatory infiltrate. Tissue was collected from 56
patients with gastro-oesophageal cancer and from 12 healthy controls. Tissue cytokine mRNA concentrations were measured by
real-time PCR and tissue protein concentrations by cytometric bead array. The degree of chronic inflammatory cell infiltrate was
recorded. Serum cytokine and acute phase protein concentrations (including C-reactive protein (CRP)) were measured by enzyme-
linked immunosorbent assay. Proinflammatory cytokines were significantly overexpressed (interleukin (IL)-1b, IL-6, IL-8 and tumour
necrosis factor-a) both at mRNA and protein levels in the cancer specimens compared with mucosa from controls. Interleukin-1b
was expressed in greatest (10–100-fold) concentration and protein levels correlated significantly with systemic inflammation (CRP)
(P¼ 0.05, r¼ 0.31). A chronic inflammatory infiltrate was observed in 75% of the cancer specimens and was associated with systemic
inflammation (CRP: P¼ 0.01). However, the presence of chronic inflammation per se was not associated with altered cytokine
expression within the tumour. Both a chronic inflammatory infiltrate and systemic inflammation (CRP) were associated with reduced
survival (P¼ 0.05 and P¼ 0.03, respectively). Tumour chronic inflammatory infiltrate and tumour tissue IL-1b overexpression are
potential independent factors influencing systemic inflammation in oesophagogastric cancer patients.
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Systemic inflammation has been found in association with the
majority of advanced solid epithelial malignancies and at the time
of diagnosis up to 50% of patients may have an elevated acute
phase protein response (APPR) (Falconer et al, 1995). The
presence of an APPR has been associated with weight loss, the
presence of hypermetabolism and anorexia, extent of disease,
the development of recurrence in advanced cancer, and adverse
prognosis (independent of stage of disease) (Rashid et al, 1982;
Kodama et al, 1999; McMillan et al, 2001, 2003; Nozoe et al, 2001;
Forrest et al, 2003). In patients with gastric cancer, the presence of
systemic inflammation has been associated with a markedly
reduced median survival (9 vs 53 weeks, Po0.001) (Rashid et al,
1982). Similarly, a study from Japan has identified a shortened
survival in oesophageal cancer patients with an elevated serum C-
reactive protein (CRP) at the time of diagnosis (Nozoe et al, 2001).
More recently, a group from the UK has identified elevated serum
CRP and reduced serum albumin concentrations as independent
prognostic indicators among patients with inoperable gastro-
oesophageal cancer (Crumley et al, 2006). The systemic inflam-
matory response is highly complex and is modulated, in part, by
the interaction of pro- and anti-inflammatory cytokines. However,
the precise origin of systemic inflammation among cancer patients
remains obscure.
Human cancer cell lines have been shown to produce
proinflammatory cytokines (Gelin et al, 1991; Strassmann et al,
1993a, b; Wigmore et al, 2002). However, such proinflammatory
cytokines are not reliably detected in the circulation and probably
act locally to promote inflammation and activate host inflamma-
tory cells (e.g. peripheral blood mononuclear cells: PBMCs)
passing through the tumour (Falconer et al, 1994; O’Riordain
et al, 1999). Such cells can re-enter the circulation and release
cytokines at distant target organs (e.g. the liver). More recently,
Martignoni et al (2005) have suggested that interleukin (IL)-6
overexpression in pancreatic cancer patients is related to the
ability of certain IL-6 producing tumours to sensitise PBMC and
induce IL-6 expression in PBMCs. The main cytokines influencing
the APPR in humans are thought to include IL-6, IL-1b, and
tumour necrosis factor-a (TNF-a) (O’Riordain et al, 1999).
Interleukin-6 is the main inducer of the APPR in human
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hepatocytes and both IL-1b and TNF-a are capable of inducing
IL-6 production from both tumour and host cells (Strassmann et al,
1993a, b). In cancer patients, the rates of production of IL-6 from
isolated PBMCs can be linked to markers of systemic inflammation
such as CRP (O’Riordain et al, 1999). The presence of such an acute
phase reaction may then be used as an indirect marker of
proinflammatory cytokine activity (IL-1b, IL-6, and TNF-a).
The source of the proinflammatory stimulus in advanced cancer
remains unclear. It has been hypothesised that in patients with
cancer, either the tumour cells or the host cells or a combination of
the two are responsible for the production of the proinflammatory
cytokines that induce the APPR. With a view to modulation of
systemic inflammation in cancer, we hypothesise that dominant
cytokines within tumour tissue drive the systemic inflammatory
response and that these might be considered as targets for specific
therapy. To investigate the role of tumour tissue in the genesis of
systemic inflammation in cancer patients, we measured cytokine
(IL-1b, IL-6, IL-8, and TNF-a) mRNA and protein concentrations
in tumour tissue collected from patients with gastro-oesophageal
cancer and tissue from healthy controls and related these
measurements to systemic concentrations of cytokines and acute
phase proteins (APPs). We also investigated the significance of a
chronic inflammatory cellular infiltrate within these tissues and
related these findings to tissue cytokine concentrations and to
clinical outcome.
PATIENTS AND METHODS
Study patients
Patients diagnosed with gastric or oesophageal cancer within the
Lothian and Borders regions between June 2002 and March 2004
were eligible for inclusion into the study. Patients were recruited at
the time of diagnosis and all subjects provided written informed
consent and the study received ethical permission from the
Lothian Research Ethics Committee. All patients who had surgery
were eligible and were studied. No patients were excluded or
refused consent. Patients not suitable for surgical resection
(advanced disease stage or comorbidity) were excluded from the
study. Patients were staged according to the International Union
Against Cancer (UICC), and final histopathological stage (pTNM)
was used in all cases (Sobin and Wittekind, 2003). Tumours
located around the oesophago –gastric junction were classified
according to Siewert and those classified as types I and II were
staged as oesophageal tumours and type III as gastric cancers
(Siewert and Stein, 1998). All clinical and pathological information
was collected prospectively, including documentation of the use
of nonsteroidal anti-inflammatory drugs (NSAIDs) and any other
therapeutic agents that may influence the inflammatory response.
Determination of serum APP and cytokine concentrations
A random blood was collected from patients at the time of
diagnosis and before any therapeutic intervention. All patients
were free from infection at the time of blood collection. Samples
were collected simultaneously from 22 healthy controls for
comparison. Serum was obtained by collecting whole blood into
lithium-heparinised tubes and centrifuging at 2000 r.p.m. for
10 min at 101C (Mistral 3000i, Thermo Life Sciences, Basingstoke,
UK). Aliquots were stored at 801C until batch analysis.
C-reactive protein was determined using an immunoturbidi-
metric assay (Abbott TDX, Abbott Laboratories, Maidenhead, UK).
A level above 10 mg l1 defined the presence of an APPR. Serum
albumin concentrations were measured by an automated bromo-
cresol green dye-binding technique. The remaining APPs were
determined by sandwich enzyme-linked immunosorbent assay as
described previously (Wigmore et al, 2002). Briefly, 96-well plates
were coated with 100 ı`l primary antibody (concentration 10 mg l1)
and incubated overnight at 41C (Dako, Ely, UK). The plates were
washed with 0.1% Tween and diluted sera (100 ml) was added to the
coated wells and incubated at room temperature for 2 h. Plates
were washed as before and a secondary antibody conjugated with
peroxidase was added to each well and incubated for 1 h (Dako,
Ely, UK). The substrate used was OPD (Dako, Ely, UK) and the
reaction was stopped with 0.5 M sulphuric acid. Plates were read
at 490 nm using a Dynatech MR5000 automated plate reader.
Standard curves were generated using standard APPs supplied by
the manufacturer (Dako, Ely, UK).
Serum cytokines were analysed with module kits and performed
according to the manufacturers instructions (Caltag, Bender
MedSystems, Towcester, UK). The lower limit of sensitivity for
each assay was; o1 pg ml1 IL-1b, 1.4 pg ml1 IL-6, 11 pg ml1
IL-8, 0.8 pg ml1 IL-10, and 5.8 pg ml1 TNF soluble receptor
(sTNF-R).
Tissue cytokine mRNA and protein measurement
Tissue collection Tissue was obtained from 56 patients at the time
of surgical resection. A representative sample of tumour tissue was
collected from each patient and tissues were snap frozen in liquid
nitrogen before storage at 801C until further analysis. An
additional 12 patients were recruited as healthy controls. These
patients underwent endoscopy as an elective procedure for
investigation of dyspeptic-type symptoms. In all instances, the
result of the procedure was normal, including both macroscopic
and microscopic assessment. Mucosal tissue (seven oesophageal
and five gastric) samples were collected from these patients with
biopsy forceps at the time of endoscopy. All control subjects were
considered healthy without established comorbidity or taking
regular medications.
Quantitative reverse transcription–polymerase chain
reaction (Q-RT – PCR)
RNA isolation and RT Total RNA was isolated from tissue
samples using the RNeasy kit (Qiagen Inc., Crawley, UK). RNA
quality and integrity was assessed using an Agilent 2100
bioanalyser (Agilent Technologies Ltd, Chesire, UK) in five
randomly selected samples. For the remaining samples, purity
and concentration were determined using spectrophotometry
(Ultrospec 2000, Pharmacia Biotech, Bucks, UK). Reverse tran-
scription was performed using 1 mg of total RNA following DNase
treatment (Qiagen Inc., UK). All RNA samples were checked for
genomic DNA contamination before RT using conventional RT–
PCR. Two microlitres of total RNA was mixed with 1 ml MgCl
(25 mM), 2.5 ml 10 Taq DNA polymerase buffer with added MgCl,
2.5ml dNTP (10 mM), 5 ml forward and reverse primers (10 mM),
11 ml DEPC-treated water and 1 ml Taq DNA polymerase (5 U ml1)
(all reagents Promega, Southampton, UK). Primers for cytochrome
b were used to detect DNA contamination. The forward primer
sequence was GGTTCTGGAATAAGAATATAGG and the reverse
primer sequence GACAACACAGTAAGAACCAGG, giving a pro-
duct of 367 bp if contamination was present.
Reverse transcription was performed once DNA contamination
had been excluded. The reaction mixture included the RNA (1 mg
in 10 ml DEPC-treated water), 4 ml MgCl (25 mM), 2 ml 10 reverse
transcriptase buffer, 2 ml dNTPs (10 mM), 1 ml random hexamers
(500mg ml1), 1.5 ml AMV reverse transcriptase (10 U ml1), and
0.5ml recombinant RNase inhibitor (40 Uml1) (all reagents
Promega, Southampton, UK). Reverse transcription was performed
at 421C for 60 min followed by 951C for 5 min.
Real-time PCR Quantitative PCR was performed using the ABI
PRISM 770 real-time Sequence Detection System (Applied
Biosystems, Warrington, UK). Reactions were performed in 50 ml
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total volume, consisting of; 25 ml Taqman universal PCR master-
mix (UNG  2), 14 ml primer/probe mix, 2.5 ml ribosomal 18S
primer/probe mix (all reagents Applied Biosystems, UK), 3.5 ml
DEPC-treated water, and 5 ml cDNA. Each sample was analysed in
duplicate. The reaction conditions were 2 min at 501C, 10 min at
951C, and 40 cycles with 15 s at 951C and 1 min at 601C. Genes
studied included IL-1b, IL-6, IL-8, and TNF-a. The primers and
probes were designed by Applied Biosystems, UK.
Quantification of gene expression was calculated using the
comparative (DDCT) method, where samples were compared with
the positive control (Bustin, 2000). The level of gene expression
within each sample was adjusted to an internal control (human
ribosomal 18S) before expression was calculated as a percentage of
the level of gene expression by the control sample. Samples that
generated cycle numbers above 23 for the endogenous control
(18S) were discarded and the samples were repeated.
Positive control Whole blood was collected from healthy donors
and the white cells were isolated using histopaque (Sigma, Dorset,
UK). The cells were cultured in lipo-polysaccharide (Sigma,
Dorset, UK) for 48 h before isolation of the RNA. Total RNA was
reverse transcribed as described above. Each real-time reaction
used an aliquot from the stock solution of cDNA as a positive
control.
Extraction of tissue protein Tissue lysates were prepared by
homogenising 50 mg of tissue in 400 ml tissue homogenising buffer
(0.4 ml 500 mM Tris, 0.2 ml 100 mM ATP, 1 ml 50 mM MgCl2, 10 ml
dithiothreitol, 1 protease inhibitor, 8.4 ml water – Sigma, Dorset,
UK). Samples were heated to 951C for 5 min before centrifuging at
13 000 r.p.m. for 30 min. Protein concentration of the supernatants
was determined by the Bradford method (Bio-Rad, Hemel
Hempstead, UK) (Bradford, 1976). Samples were stored at 801C
until analysis.
Determination of tissue cytokine concentrations
Cytokine protein concentrations were determined using the
Cytometric Bead Array System according to manufacturer’s
instructions (Human Inflammation Kit, BD Biosciences, Oxford,
UK). This kit allows the measurement of cytokines IL-1b, IL-6, IL-
8, IL-10, IL-12p70, and TNF-a. Briefly, 50 ml of tissue extract was
added to the reaction mix containing antibody-coated microbeads
and incubated at room temperature for 3 h. Cytokine concentra-
tions were determined by flow cytometry (BD FACScan, Oxford,
UK). Results were calculated to take into account the total protein
concentration of the tissue lysate and are expressed as pg mg1 of
total protein. Intra-assay variability ranged between 2 and 10% and
interassay variability was 4–15%.
Histological analysis
Representative sections of tumour tissue were fixed with formalin
and stained with haematoxylin and eosin. A single Consultant
pathologist (HG) reviewed all the tissue sections and the extent of a
chronic inflammatory cellular infiltrate was recorded. Sections
were classified as either diffuse scanty (occasional) chronic
inflammatory cells present, focal lymphoid aggregates only, diffuse
chronic inflammatory cellular infiltrate present throughout the
tissue, or patchy chronic inflammatory cells present (Figure 1). HG
was blinded to the clinical data, serum APP/cytokine concentra-
tions, and tissue cytokine concentrations relating to each patient.
Statistical analysis
Comparisons between groups of continuous variables were made
by the Mann–Whitney U-test. Categorical variables were com-
pared by Fisher’s exact test. Correlations between continuous
variables were assessed by Spearman’s rank correlation coefficient.
Survival between groups was analysed by the log-rank test and
Cox’s proportional hazards model. A P-value p0.05 was
considered statistically significant.
RESULTS
Study patients
Patient demographics are shown in Table 1. Subgroup analysis
confirmed no significant differences in either tissue mRNA or
A
B
C
Figure 1 Representative photomicrographs taken from three patients
with poorly differentiated adenocarcinoma of the oesophagus. Patient (A)
demonstrates minimal/no inflammatory cell reaction. Patient (B) has a
patchy chronic inflammatory cell infiltrate. Patient (C) shows a diffuse
chronic inflammatory cellular infiltrate present throughout the tumour.
Sections of tumour tissue were fixed with formalin and stained with
haematoxylin and eosin (magnification  100).
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protein levels between patients who received preoperative
chemotherapy and those who did not (data not shown). Similarly,
there were no differences in tissue mRNA or protein levels or
serum cytokine or APP levels among those patients taking NSAIDs
or any other therapeutic agents that may modify the inflammatory
response (data not shown). Therefore, all patients were included as
a single group for analysis.
Serum cytokine and APP concentrations
Serum APP concentrations for the study patients and healthy
controls are shown in Table 2. The patient group had significantly
elevated concentrations of positive APPs compared with the
control population; CRP (Po0.001, Mann–Whitney U-test),
haptoglobin (Po0.001), and a1-antichymotrypsin (Po0.001).
There was no difference in concentrations of the negative acute
phase reactants; albumin (P¼ 0.242) or transferrin (P¼ 0.346).
Ten (18%) patients had a serum CRP concentration 410 mg l1,
which was associated with reduced survival duration (P¼ 0.031,
log-rank test) (Figure 2). C-reactive protein concentration
remained an independent prognostic indicator on multivariate
analysis when analysed with stage, age, sex, and grade (P¼ 0.048,
hazard ratio 2.7 (1.1– 7.3 95% CI); Cox’s proportional hazards
model).
Serum cytokine concentrations were similar between the healthy
controls and cancer patients (Table 2). Serum cytokine concentra-
tions did not correlate with serum APP concentrations (linear
regression, data not shown) and patients with CRP levels greater
than 10 mg l1 did not have significantly elevated serum cytokine
concentrations.
Tissue cytokine mRNA and protein concentrations
Interleukin-6 and IL-8 mRNA were not measurable in any of the
gastro-oesophageal mucosa samples collected from healthy con-
trols and IL-1b and TNF-a were only detectable at very low
concentrations (Figure 3A). In contrast, mRNA for IL-1b, IL-6,
IL-8, and TNF-a were detected in tumour tissue at significantly
elevated concentrations: IL-1b Po0.001; IL-6 Po0.001; IL-8
Po0.001; TNF-a P¼ 0.006 (see Figure 3A).
Similarly, IL-6 protein was not detected in mucosal tissue
samples from healthy controls and IL-1b, IL-8, and TNF-a were
only measured at low concentrations (median concentrations;
IL-1b 2.6 pg mg1 total protein, IL-8 0.2 pg mg1 total protein,
TNF-a 0.1 pg mg1 total protein). However, cytokine protein con-
centrations were significantly elevated in the tumour tissue: IL-1b
Table 1 Study patient demographics (n¼ 56)
Number (%)
Age (years)a 66 (58–75)
Sex
Male 40 (71)
Female 16 (29)
Tumour site
Oesophageal 26 (46)
Oesophago–gastric junction 13 (23)
Gastric 17 (30)
Histology
Adenocarcinoma 52 (93)
Squamous cell carcinoma 4 (7)
Grade
Well differentiated 4 (7)
Moderately differentiated 24 (43)
Poorly differentiated 28 (50)
UICC stage
1 17 (30)
2 13 (23)
3 21 (38)
4 5 (9)
Treatment undertaken
Oesophagectomy 25 (45)
Gastrectomy 18 (32)
Preoperative chemotherapy followed by surgery 13 (23)
Status
Alive 37 (66)
Dead 19 (34)
aValues given are median (interquartile range).
Table 2 Serum concentrations of acute phase proteins and cytokines for
the patient group (n¼ 56) and healthy controls (n¼ 22)
Patient group (n¼56)Control group (n¼ 22)P-valuea
CRP (mg/l) 4 (2–16) 1 (1–3) o0.001
Haptoglobin (mg/l) 1869 (1421–2651) 821 (627–1157) o0.001
ACT (mg/l) 409 (326–502) 245 (213–261) o0.001
Albumin (g/l) 42 (39–44) 42 (39–45) 0.227
Transferrin (mg/l) 2076 (1565–2648) 2197 (1861–2451) 0.478
IL-1b (pg/ml) 0b 0 —
IL-6 (pg/ml) 0 (0–91) 11 (0–214) 0.412
IL-8 (pg/ml) 0 (0–57) 0 (0–118) 0.683
IL-10 (pg/ml) 0c 0 —
sTNF-R (ng/ml) 2.6 (1.3–4.1) 2.8 (1.3–3.6) 0.559
ACT¼ a1-antichymotrypsin; CRP¼C-reactive protein; IL¼ interleukin; sTNF-
R¼ soluble tumour necrosis factor receptor (p55). Positive acute phase protein
concentrations were elevated in the patient group compared with the control group.
There were no differences between concentrations of the negative acute phase
reactants or serum cytokines. aMann–Whitney U-test. bOnly two patients had
measurable serum IL-1b concentrations. cOnly four patients had measurable IL-10
concentrations. Values are median (interquartile range).
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Figure 2 Kaplan–Meier survival plot presented by serum CRP
concentration. Heavy line CRP 410 mg l1 (median survival 509 days) vs
light line CRPo10 mg l1 (median survival4900 days); P¼ 0.031, log-rank
test.
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136 pg mg1 of total protein (IQR 41–425), P¼ 0.007; IL-6
3 pg mg1 (IQR 0 –46), Po0.05; IL-8 56 pg mg1 (IQR 23–159),
P¼ 0.007; TNF-a 7 pg mg1 (IQR 1– 26), Po0.05 (Figure 3B). Of
note, IL-1b concentrations were found at appreciably higher
concentrations compared with the other cytokines (10–100-fold
increase).
There was no correlation between tissue cytokine mRNA
concentrations and cytokine tissue protein concentrations; IL-1b
(P¼ 0.64, r¼ 0.07; Spearman’s rank), IL-6 (P¼ 0.46, r¼0.1),
IL-8 (P¼ 0.55, r¼ 0.09), TNF-a (P¼ 0.90, r¼ 0.02). Increased
mRNA concentrations were not associated with elevated tissue
cytokine protein concentrations.
Tissue cytokine mRNA concentrations did not correlate with
serum cytokine concentrations or serum APP concentrations (data
not shown). However, tumour tissue IL-1b protein levels were
positively correlated with serum CRP concentrations (P¼ 0.05,
r¼ 0.31; linear regression) (Figure 4). Although TNF-a protein
levels did not correlate with serum cytokine/APP concentrations
there was a significant correlation between sTNF-R and serum
CRP concentrations (P¼ 0.03, r¼ 0.36). There was no correlation
between tumour tissue IL-6 and either circulating IL-6 or APP
concentrations. There was also a trend towards a correlation
between tumour IL-8 protein concentrations and serum sTNF-R
concentrations, but this did not quite reach statistical significance
(P¼ 0.06, r¼ 0.32).
Histological analysis
Histology from three patients recruited to the study could not be
traced; therefore, 53 tumour sections were studied. Twenty-four
(45%) tumour samples were classified as having scanty diffuse or
patchy chronic inflammatory cells. Sixteen (30%) tumour samples
had a diffuse chronic inflammatory cellular infiltrate visible
throughout the whole tumour. The remaining 13 (25%) tumour
sections had focal lymphoid aggregates only. When compared with
tumour sections possessing lymphoid aggregates alone, tissues
with a diffuse or patchy inflammatory cellular infiltrate were
associated with elevated serum CRP and sTNF-R concentrations
(P¼ 0.01 and P¼ 0.007, respectively, Mann–Whitney U-test)
(Figure 5). In addition, a chronic inflammatory cellular response
was associated with reduced prognosis (P¼ 0.05, log-rank test)
(Figure 6). A chronic inflammatory infiltrate remained an
independent prognostic indicator on multivariate analysis when
analysed with stage, age, sex, tumour grade, and serum CRP
concentrations (P¼ 0.013, hazard ratio 7.7 (1.5–38.0 95% CI);
Cox’s proportional hazards model).
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Figure 4 A scatter plot illustrating the relationship between serum CRP
concentrations and tumour tissue IL-1b protein concentrations (P¼ 0.05,
r¼ 0.31; linear regression).
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There was no correlation between the presence of a chronic
inflammatory cell infiltrate and serum cytokine concentrations.
Six (11%) patients had histological evidence of Helicobacter
pylori on the resected specimens. A chronic inflammatory cellular
infiltrate was not associated with H. pylori infection (P¼ 0.67,
Fisher’s exact test).
Tumour necrosis was evident in 13 (25%) samples, including
four samples collected from patients who received preoperative
chemotherapy, but there was no association between treatment
modality and the presence of tumour necrosis (P¼ 0.92, w2 test).
The presence of tumour necrosis was associated with elevated
serum haptoglobin but not CRP concentrations (P¼ 0.045 and
P¼ 0.07, respectively, Mann–Whitney U-test). Tumour necrosis
was not associated with differences in tissue cytokine concentra-
tions or survival (P¼ 0.62, log-rank test).
Tissue cytokine (IL-1b, IL-6, IL-8, and TNF-a) mRNA and
protein levels were found at similar concentrations within tumour
tissues with a chronic inflammatory cell infiltrate and tumour
samples with lymphoid aggregates alone.
DISCUSSION
In this study, we have shown that patients with gastro-oesophageal
malignancy have elevated serum concentrations of APPs but
similar serum proinflammatory cytokine concentrations compared
with a control population. A range of proinflammatory cytokine
concentrations (mRNA and protein) were significantly elevated in
tumour tissue compared with tissue sampled from healthy
controls. However, only IL-1b correlated with markers of systemic
inflammation (CRP). In addition, a chronic inflammatory cellular
infiltrate within the tumour was associated with elevated serum
APP concentrations and reduced survival, but was not associated
with elevated tissue cytokine mRNA and protein concentrations.
An APPR has been well documented among patients with
cancer, including gastric and oesophageal malignancies, and an
elevated serum CRP has been identified as an adverse prognostic
indicator, independent of stage of disease, among these patients
(Rashid et al, 1982; Falconer et al, 1995; Kodama et al, 1999;
McMillan et al, 2001, 2003; Nozoe et al, 2001; Forrest et al, 2003).
The present study has confirmed these findings. Patients with
gastro-oesophageal cancer had significantly elevated serum con-
centrations of positive APPs compared with healthy controls.
Moreover, the 10 (18%) patients with a CRP concentration above
10 mg l1 at diagnosis had a reduced survival interval, which was
independent of disease stage. Our study did not demonstrate any
differences in serum cytokine concentrations between cancer
patients and controls. Although some studies have shown an
association between serum cytokines and APPs (Martignoni et al,
2005) several have failed to demonstrate such a link and
determination of serum cytokines remains an unreliable measure
of tissue cytokine activity (Falconer et al, 1994; Barber et al, 1999).
Moreover, these findings suggest that circulating cytokines may
not be the key mediators of the APPR.
Proinflammatory cytokine mRNA and protein concentrations
were either not detectable or found at low levels in tissue collected
from healthy controls. In contrast, mRNA and cytokine protein
concentrations were measured at significantly higher concentra-
tions in tumour tissue. In all instances, tissue cytokine concentra-
tions were significantly elevated in tumour tissue compared with
tissue from healthy controls. These findings are supported by Yuan
et al (2000) who investigated IL-8 mRNA concentrations in tumour
tissue and adjacent normal lung tissue among patients with non-
small-cell lung cancer and also found increased cytokine expres-
sion within the tumour tissue. Other groups have similarly
demonstrated increased tissue cytokine concentrations associated
with progression along the metaplasia –dysplasia– carcinoma
sequence in Barrett’s oesophagus (Tselepis et al, 2002; Dvorakova
et al, 2004).
In the present study, median IL-1b concentrations were 10–100-
fold higher than IL-6 in the tumour tissue and there was a weak but
significant correlation between tumour tissue IL-1b concentration
and serum CRP. There was a similar trend with IL-8. Both IL-1b
and IL-8 are recognised as important cytokines in the generation
of the systemic inflammatory response and it is possible that high
tissue concentrations of these cytokines stimulate PBMCs as they
pass through the tumour mass, which in turn act on target organs,
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Figure 5 A diffuse or patchy inflammatory cellular infiltrate was
associated with elevated serum CRP concentrations (P¼ 0.01, Mann–
Whitney U-test). Thick bar represents median, the box represents quartiles,
and lines represent extreme values.
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Figure 6 Kaplan–Meier survival plot presented by the presence or
absence of a chronic inflammatory cellular infiltrate within the tumour. The
heavy line represents the presence of a chronic inflammatory infiltrate vs
focal lymphoid aggregates alone, light line (P¼ 0.05; log-rank test).
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such as the liver, to induce the synthesis of APPs that are
associated with systemic inflammation. Previously, we have
demonstrated that PBMC from weight-losing pancreatic cancer
patients control the hepatic APPR by a primarily IL-6-dependent
mechanism (O’Riordain et al, 1999). Moreover, Martignoni et al
(2005) have suggested that IL-6 overexpression in cachectic
pancreatic cancer patients is related to the ability of certain IL-6
producing tumours to sensitise PBMC and induce IL-6 expression
in PBMCs. In the latter study, screening by DNA microassay
analysis followed by quantitative PCR identified only IL-6 mRNA
expression to be significantly increased in tumour samples of
cachectic patients compared with noncachectic patients or
pancreas samples from normal controls. Immunohistochemistry
suggested the source of IL-6 to be tumour cells rather than host
cells. The results of the present study, however, identify that at
least in patients with gastro-oesophageal cancer IL-1b rather than
IL-6 may be important as an initiator of the proinflammatory
APPR. Interleukin-6 may form a common final pathway via
activated PBMCs. Interestingly, in the colon-26 murine model of
cancer cachexia associated with systemic inflammation there
appears to be a complex intratumoural amplification loop between
IL-1b and IL-6, which can be downregulated by IL-10 (Yasumoto
et al, 1995; Fujiki et al, 1997).
In this study, we did not find any correlation between tissue
cytokine mRNA concentrations and systemic cytokines or APP
concentrations. Raddatz et al (2005) did identify an association
between tissue cytokine mRNA levels and systemic CRP concen-
trations in Crohn’s disease. These differing results may be partly
explained by the lack of correlation between tissue mRNA
concentrations and protein concentrations in this study. Although
some groups have demonstrated a correlation between IL-1b and
IL-6 mRNA and protein concentrations in an animal model of
inflammatory joint disease, they also failed to show any correlation
for TNF-a mRNA and protein concentrations (Rioja et al, 2004).
The difficulties of relating mRNA concentrations to protein
concentrations has been extensively documented elsewhere, but
it is also important to consider that real-time PCR is an exquisitely
sensitive technique and that what we are detecting in some
patients, although elevated, may have little or no functional
significance as it may not be translated into protein. Cytokine
protein concentrations are, therefore, likely to be a more robust
measure of tissue cytokine activity than mRNA levels.
A chronic inflammatory cellular infiltrate was noted in 40 (75%)
tumour samples and was associated with elevated levels of serum
CRP and sTNF-R. In addition, a chronic inflammatory infiltrate
was associated with reduced survival. The presence of an
inflammatory infiltrate within tumours and its relevance to
prognosis has been investigated in a number of cancer types.
Tumour-associated macrophages have been associated with
reduced disease-free survival among lung, head and neck, and
endometrial cancer (Marcus et al, 2004; Ohno et al, 2004; Chen
et al, 2005). In contrast, increased numbers of tumour-associated
macrophages, eosinophils, mast cells, and lymphocytes have been
linked with improved survival in colorectal cancer (Svennevig
et al, 1984; Jass, 1986; Nielsen et al, 1999). The prognostic
significance of tumour-associated inflammatory cells is less clear
in gastro-oesophageal cancer. An increased macrophage infiltrate
was associated with more advanced stage of disease among
patients with gastric cancer in one study, whereas other studies
have suggested a more favourable prognosis associated with a
more pronounced macrophage infiltration (Heidl et al, 1987;
Tsujitani et al, 1987; Ohno et al, 2003). Similarly, increasing
tumour-infiltrating lymphocyte count has been linked with
decreased risk of death from gastric cancer in one study, but
associated with an adverse prognosis in another (Setala et al, 1996;
Grogg et al, 2003). Studies relating to oesophageal cancer are
equally contradictory (Ma et al, 1999; Koide et al, 2004). In this
study, there were no differences in tissue cytokine concentrations
(mRNA or protein) between tumours with a chronic inflammatory
infiltrate and those without, suggesting that differential tissue
IL-1b expression is likely to be tumour-cell derived.
Laser capture microdissection (LCM) enables single cell types to
be separated from multiple cell populations and would have been
helpful in separating our tissue samples into pure tumour cell
and inflammatory cell populations (Emmert-Buck et al, 1996).
This technique was attempted initially but abandoned owing to
inconsistent results, which were related to poor RNA quality as a
consequence of this technique. In addition, our results have shown
a lack of correlation between mRNA levels and functional protein
concentrations, questioning the relevance of measuring mRNA
concentrations. Determining cellular cytokine protein concentra-
tions by the cytometric bead array system following LCM was not
possible owing to the low protein concentrations that were
retrieved.
Tumour necrosis was evident in 25% of tissue samples and was
not associated with receipt of preoperative chemotherapy. The
presence of tissue necrosis was weakly associated with elevated
serum APP concentrations and may be explained by the necrotic
tissue behaving like an abscess and inducing a predominantly
acute inflammatory response. Tissue necrosis did not have any
prognostic value in this study.
In conclusion, systemic inflammation is associated with
adverse prognosis in gastro-oesophageal cancer. Tumour tissue
cytokine concentrations are elevated compared with healthy
controls and IL-1b concentrations are positively associated with
some markers of systemic inflammation. In addition, the presence
of a chronic inflammatory cell infiltrate into the tumour is also
associated with markers of systemic inflammation and reduced
survival, but is not associated with differential expression of tissue
preinflammatory cytokine concentrations. This raises the possibi-
lity that the role of the chronic inflammatory infiltrate in the
generation of systemic inflammation may be independent of
differential expression of proinflammatory cytokines by these cells.
Different mediators or cell–cell interactions may be more
important for their effects.
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